Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 62

1.

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.

Charpentier C, Choquet M, Joly V, Yeni P, Visseaux B, Caseris M, Brun-Vézinet F, Yazdanpanah Y, Peytavin G, Descamps D, Landman R.

J Antimicrob Chemother. 2014 Jun 19. pii: dku211. [Epub ahead of print]

PMID:
24948705
[PubMed - as supplied by publisher]
2.

French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.

Hoen B, Bonnet F, Delaugerre C, Delobel P, Goujard C, L'Hénaff M, Persiaux R, Rey D, Rouzioux C, Taburet AM, Morlat P; 2013 French HIV expert group.

J Int AIDS Soc. 2014 Jun 17;17:19034. doi: 10.7448/IAS.17.1.19034. eCollection 2014.

PMID:
24942364
[PubMed - in process]
Free PMC Article
3.

Impact of randomized antiretroviral therapy initiation on glucose metabolism.

Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Melbourne KM, Ha B, McComsey GA.

AIDS. 2014 Jun 19;28(10):1451-61. doi: 10.1097/QAD.0000000000000266.

PMID:
24637543
[PubMed - in process]
4.

Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.

Hattab S, Guihot A, Guiguet M, Fourati S, Carcelain G, Caby F, Marcelin AG, Autran B, Costagliola D, Katlama C.

BMC Infect Dis. 2014 Mar 4;14:122. doi: 10.1186/1471-2334-14-122.

PMID:
24589015
[PubMed - in process]
Free PMC Article
5.

Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment.

Manzardo C, Gatell JM.

AIDS Rev. 2014 Jan-Mar;16(1):35-42.

PMID:
24584107
[PubMed - in process]
6.

Effectiveness of efavirenz compared with ritonavir-boosted protease inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.

Imaz A, Llibre JM, Navarro J, Curto J, Clotet B, Crespo M, Ferrer E, Saumoy M, Tiraboschi JM, Murillo O, Podzamczer D.

Antivir Ther. 2014 Jan 23. doi: 10.3851/IMP2736. [Epub ahead of print]

PMID:
24458091
[PubMed - as supplied by publisher]
7.

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.

Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Tebas P, Melbourne K, Ha B, Jahed NC, McComsey GA.

AIDS. 2013 Aug 24;27(13):2069-79. doi: 10.1097/QAD.0b013e328361d25d.

PMID:
24384588
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting.

Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, Salpietro S, Carbone A, Lazzarin A.

Ther Clin Risk Manag. 2014;10:9-15. doi: 10.2147/TCRM.S49428. Epub 2013 Dec 18.

PMID:
24379676
[PubMed]
Free PMC Article
9.
10.

Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.

[No authors listed]

Prescrire Int. 2013 Oct;22(142):233-5.

PMID:
24298581
[PubMed - indexed for MEDLINE]
11.

Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202.

McComsey GA, Kitch D, Sax PE, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Daar ES.

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):167-74. doi: 10.1097/01.qai.0000437171.00504.41.

PMID:
24121755
[PubMed - indexed for MEDLINE]
12.

Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.

Casado JL, de Los Santos I, Del Palacio M, García-Fraile L, Pérez-Elías MJ, Sanz J, Moreno S.

HIV Clin Trials. 2013 Jan-Feb;14(1):1-9. doi: 10.1410/hct1401-1.

PMID:
23372109
[PubMed - indexed for MEDLINE]
13.

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.

Andersson LM, Vesterbacka J, Blaxhult A, Flamholc L, Nilsson S, Ormaasen V, Sönnerborg A, Gisslén M.

Scand J Infect Dis. 2013 Jul;45(7):543-51. doi: 10.3109/00365548.2012.756985. Epub 2013 Jan 7.

PMID:
23294034
[PubMed - indexed for MEDLINE]
14.

Efavirenz outperforms boosted atazanavir among treatment-naive HIV-1-infected persons in routine clinical care.

Taniguchi T, Grubb JR, Nurutdinova D, Önen NF, Shacham E, Donovan M, Overton ET.

J Int Assoc Provid AIDS Care. 2013 Mar-Apr;12(2):138-41. doi: 10.1177/1545109712467057. Epub 2012 Dec 26.

PMID:
23269514
[PubMed - indexed for MEDLINE]
15.

Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.

McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M.

J Infect Dis. 2013 Feb 15;207(4):604-11. doi: 10.1093/infdis/jis720. Epub 2012 Nov 29.

PMID:
23204164
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.

Mollan K, Daar ES, Sax PE, Balamane M, Collier AC, Fischl MA, Lalama CM, Bosch RJ, Tierney C, Katzenstein D; AIDS Clinical Trials Group Study A5202 Team.

J Infect Dis. 2012 Dec 15;206(12):1920-30. doi: 10.1093/infdis/jis613. Epub 2012 Nov 12.

PMID:
23148287
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.

Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, Fischl MA, Collier AC, Haas DW; DS Clinical Trials Group.

J Infect Dis. 2013 Feb 1;207(3):420-5. doi: 10.1093/infdis/jis690. Epub 2012 Nov 12.

PMID:
23148286
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.

Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, Günthard HF; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):28-35. doi: 10.1097/QAI.0b013e318274e2b0. Erratum in: J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e170-1.

PMID:
23018371
[PubMed - indexed for MEDLINE]
19.

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.

Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Di Giambenedetto S, Borghi V, Penco G, Cicconi P, Francisci D, Sterrantino G, Zoncada A, Monno L, Capetti A, Giacometti A; ARCA Collaborative Group.

J Antimicrob Chemother. 2013 Jan;68(1):200-5. doi: 10.1093/jac/dks339. Epub 2012 Aug 21.

PMID:
22915463
[PubMed - indexed for MEDLINE]
Free Article
20.

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA.

JAMA. 2012 Jul 25;308(4):387-402. doi: 10.1001/jama.2012.7961.

PMID:
22820792
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk